Physician profile
Daisy Escobar
NPI 1689151383
$11,383.75
in general payments reported to CMS, 2019-2025
63 companies · $2,695 in 2025
The $2,695 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.10 · 2020: $16.88 · 2021: $343 · 2022: $2,336 · 2023: $3,495 · 2024: $2,469 · 2025: $2,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,236 · Education: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,236.03 |
| Education | $422.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,187.57 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $966.64 | 2021-2025 | Imfinzi, Calquence, Enhertu |
| Janssen Biotech, INC. | $928.44 | 2021-2025 | Erleada, Akeega, Balversa |
| Celgene Corporation | $643.15 | 2022-2025 | Reblozyl, Pomalyst, Pomalyst |
| Eisai INC. | $620.22 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $573.39 | 2022-2025 | Libtayo |
| Incyte Corporation | $562.13 | 2022-2025 | Monjuvi, Jakafi, Zynyz |
| Seagen INC. | $533.88 | 2021-2024 | Adcetris, Padcev |
| Daiichi Sankyo INC. | $438.18 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Lilly USA, LLC | $352.40 | 2022-2025 | Verzenio, Retevmo, Jaypirca |
| Merck Sharp & Dohme LLC | $319.40 | 2022-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $315.10 | 2021-2024 | Opdivo |
| Pfizer INC. | $253.01 | 2021-2025 | |
| Abbvie INC. | $251.35 | 2022-2025 | |
| Beigene USA, INC. | $241.33 | 2022-2024 | Brukinsa, Tevimbra |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $219.08 | 2023-2025 | Cabometyx |
| Amgen INC. | $205.20 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $166.73 | 2024-2025 | |
| Genentech USA, INC. | $166.29 | 2022-2025 | Polivy, Lunsumio, Tecentriq |
| Genzyme Corporation | $153.17 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $151.90 | 2024 | Tazverik, Somatuline Depot, Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $137.71 | 2022-2025 | Iclusig, Alunbrig |
| Sobi, INC | $137.46 | 2022-2025 | |
| Taiho Oncology, INC. | $122.14 | 2023-2025 | |
| Array Biopharma INC | $119.60 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Janssen Pharmaceuticals, INC | $116.90 | 2021 | |
| Tersera Therapeutics LLC | $112.04 | 2023-2025 | Zoladex, Quzyttir |
| Alexion Pharmaceuticals, INC. | $111.99 | 2025 | |
| Glaxosmithkline, LLC. | $104.39 | 2023-2025 | Ojjaara, Blenrep |
| Blueprint Medicines Corporation | $99.84 | 2021-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.88 | 2024-2025 | |
| Genmab U.S., INC. | $61.96 | 2024-2025 | Epkinly |
| Deciphera Pharmaceuticals INC. | $61.58 | 2022-2025 | Qinlock, Romvimza |
| Sumitomo Pharma America, INC. | $61.18 | 2024 | Orgovyx |
| Pharmaessentia USA Corporation | $58.46 | 2024-2025 | Besremi |
| Karyopharm Therapeutics INC. | $57.13 | 2022-2023 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $50.90 | 2023-2025 | |
| Emd Serono, INC. | $43.18 | 2024-2025 | |
| Immunocore Limited | $39.97 | 2024-2025 | Kimmtrak |
| Stemline Therapeutics INC. | $37.06 | 2023 | Orserdu |
| Astellas Pharma US INC | $35.42 | 2024-2025 | Vyloy, Xospata |
| Gilead Sciences, INC. | $34.10 | 2021-2025 | Trodelvy |
| Syndax Pharmaceuticals, INC. | $32.72 | 2025 | |
| Pharmacosmos Therapeutics INC. | $30.75 | 2022-2024 | Monoferric |
| Janssen Scientific Affairs, LLC | $30.46 | 2023 | Tecvayli, Darzalex |
| Morphosys, US INC. | $30.10 | 2023 | Monjuvi |
| Puma Biotechnology, INC. | $30.03 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $28.55 | 2024-2025 | Sancuso |
| Dendreon Pharmaceuticals LLC | $28.47 | 2024 | Provenge |
| Rigel Pharmaceuticals, INC. | $21.76 | 2023 | Rezlidhia, Tavalisse |
| Cti Biopharma Corp. | $21.32 | 2023 | Vonjo |
| Mirati Therapeutics, INC. | $17.81 | 2024 | Krazati |
| Adc Therapeutics America, INC. | $17.46 | 2024 | |
| Mallinckrodt Hospital Products INC. | $16.88 | 2020 | |
| Caris Mpi, INC. | $16.54 | 2025 | Mi Cancer Seek |
| Immunogen, INC. | $16.10 | 2023 | Elahere |
| Aveo Pharmaceuticals, INC. | $15.82 | 2023 | Fotivda |
| Beone Medicines USA, INC. | $15.44 | 2025 | Brukinsa |
| Csl Behring | $15.43 | 2019 | |
| Myriad Genetic Laboratories, INC. | $14.42 | 2025 | Myrisk |
| Shire North American Group INC | $13.67 | 2019 | |
| Myovant Sciences INC. | $12.33 | 2022 | |
| Veracyte, INC. | $12.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.